Aevi Genomic Medicine — Medgenics — Corporate Update (September 2015)
40 slides from Aevi Genomic Medicine's corporate update, Sep 9, 2015
Slide 1: NFC-1: Phase 2 Ready CNS Asset
NFC - 1: Phase 2 Ready CNS Asset September 9 , 2015
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results
Slide 3: Sections
Sections • Executive Summary • MDGN/CHOP Collaboration • neuroFix / NFC - 1 Acquisition • NFC - 1 Phase 1b Clinical Trial in ADHD • 22q11.2 Deletion Syndrome • Summary 3
Slide 4: Executive Summary
Executive Summary 4 • Medgenics will acquire neuroFix – Provides access to a Phase 2 - ready program, NFC - 1 – P rivate company f ounded by Dr. Hakonarson, Director, Center for Applied Genomics (CAG ) at The Children’s Hospital of Philadelphia (CHOP) – Breakthrough discovery: mGluR mutations cause
Slide 5: Medgenics/CHOP Collaboration
Medgenics/CHOP Collaboration 5 • C ollaboration allows MDGN option to discoveries made by CAG: – Rare and Orphan diseases – Unique, druggable targets in high - need patients • Distinct, genetically identified participants allow for rapid clinical development including: – Comparatively small trials –
Slide 6: CAG/CHOP Capabilities
CAG/CHOP Capabilities 6 Datasets (Genomics EMR) ▪ Over 60K pediatric and 150K related adult patients GWAS genotyped with associated longitudinal EMR since 2006 Data Analytics ▪ End to end internal Next - Gen sequencing capabilities ▪ Integrated bioinformatics ▪ Rapid identification of novel genetic
Slide 7: Business Model Evolution: Gene Therapy to Genomic Medicine
Business Model Evolution: Gene Therapy to Genomic Medicine 7 Diverse Limited Medgenics capabilities Ex vivo Gene Therapy • TARGT EPO • TARGT GLP - 2 Time Genomic Medicine • C ommercial capabilities • Further pipeline diversification Genomic Drug Development • World - class biobank and analytics • G
Slide 8: NFC-1, a first-in-class mGluR Neuromodulator
NFC - 1, a first - in - class Metabotopic Glutamate Receptor ( mGluR ) Neuromodulator 8
Slide 9: CAG Breakthrough Discovery
Elia, Glessner et al. Nature Genetic s, 2012 CAG Breakthrough Discovery 9 Research by Dr. Hakonarson indicated approximately 20% of ADHD patients have an underlying mGluR network mutations • 10 fold increased frequency of copy number variations (CNV ) in the mGluR gene network detected in ADHD popul
Slide 10: NFC-1, first-in-class mGluR Neuromodulator
NFC - 1, first - in - class mGluR Neuromodulator 10 • Small molecule, non - stimulant agonist of multiple mGluRs : • 1, 3, 5, 7, 8 • Up - regulates GABA B receptors • Positive effects seen in animal models • Ameliorate cognitive impairment • Reduce hyperactivity • Enhance memory • Antipsychotic acti
Slide 11: NFC-1, An Excellent Candidate for Repositioning
NFC - 1, An Excellent Candidate for R epositioning 11 • Failed on efficacy measure • Excellent safety profile in >1,000 patients • No addiction potential • Excellent oral bioavailability and predictable PK – Twice - daily dosing NFC - 1 tested in a large scale clinical trial in Vascular Dementia pat
Slide 12: GREAT Study: mGluR mutation positive adolescents with ADHD symptoms
NFC - 1 GREAT Study: mGluR mutation positive adolescents with ADHD symptoms 12
Slide 13: GREAT Study: Design and Execution
NFC - 1 GREAT Study: Design and Execution • Part 1: Single Ascending Dose(SAD)/Pharmacokinetics(PK) – SAD 24 hour PK 50 - 800mg • Part 2 : Ascending Dose Trial – 1 week of placebo followed by 4 weeks active therapy – Dose escalated: 50mg BID* - 400mg BID* weekly (x4) – Efficacy endpoints CGI, Vander
Slide 14: GREAT Study Enrolled Complex, Severe Patients
GREAT Study Enrolled Complex, Severe Patients Inclusion Criteria • ADHD patients age 12 – 17 • mGluR network mutation positive ( mGluR +) Severe ADHD symptoms and high comorbidity • 73% had severe ADHD (CGI - S >5 at baseline) • 67% had co - morbid psychiatric conditions – Anxiety, ODD, Insomnia • 3
Slide 15: Strong Efficacy Signal in Key Endpoints – CGI-I
15 Strong Efficacy Signal in Key Endpoints – CGI - I 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 1 2 3 4 5 CGI - I: Proportion of Responders at E ach Week for All Subjects W eek W eek W eek W eek W eek Treatment effect appeared more robust over time and at higher doses CGI - I, Clinical Global Impression
Slide 16: Strong Efficacy Signal in Key Endpoints – Vanderbilt Parent Rating
16 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Week 1 Week 2 Week 3 Week 4 Week 5 Vanderbilt Scores: Proportion of Patients Improved from Pre - study Baseline for All Patients Improvement defined as 25% improvement in hyperactivity/inattention domains Strong Efficacy Signal in Key Endpoints – Vanderbilt
Slide 17: Statistically Significant Improvement in Key Endpoints
Statistically Significant Improvement in Key Endpoints 17 Week 1 Week 2 Week 3 Week 4 Week 5 Mean 29.1 26.4 24.0 23.3 22.5 Week 1 Week 2 Week 3 Week 4 Week 5 Mean 3.79 3.13 2.79 2.79 2.21 P < 0.001 P < 0.001 Average Vanderbilt score at each week – all patients Average CGI - I score at the end of eac
Slide 18: mGluR Network Mutation Classification: Genetic Tiers
18 mGluR Network Mutation Classification: “Genetic Tiers” Tier 3 • 800+ Genes • 30% of ADHD Tier 2 • 279 Genes • 20% of ADHD Tier 1 • 79 Genes • 10% of ADHD Tier 1 Mutations in genes in mGluR receptors or that directly influence mGluR signaling. n=17 Tier 2 Mutations in genes that encode proteins th
Slide 19: Core Mutations (Tier1/2) Predict Higher Response – CGI-I
Core Mutations (Tier1/2) Predict Higher Response 19 0.00 0.20 0.40 0.60 0.80 1.00 Tier 1 Tier 2 Tier 3 CGI - I Proportion of Responders at Week 5 by Genetic Tier ( with 95% confidence intervals) Proportion of Responders (CGI - I) Note: genetic tiers were not balanced Note: Data is for the subset of
Slide 20: Core Mutations (Tier1/2) Predict Higher Response – Vanderbilt
20 Proportion of Responders (Vanderbilt) Note: genetic tiers were not balanced Note: Data is for the subset of patients who titrated to the highest dose (N=18) 0.00 0.20 0.40 0.60 0.80 1.00 Tier 1 Tier 2 Tier 3 Vanderbilt - Proportion of Responders at Week 5 by Genetic Tier ( with 95% confidence int
Slide 21: GREAT Study Summary
NFC - 1 GREAT Study Summary • Strong efficacy signal detected in several validated ADHD scales • Improvement in multiple symptoms noted by caregivers – I nattention, hyperactivity, anxiety, mood disorders • Treatment effect more robust over time & higher doses • Genetic biomarker predictive of respo
Slide 22: Efficacy & Safety Profile De-risk Pivotal Trials
Efficacy & Safety Profile De - risk Pivotal Trials Phase 2/3 trial in Tier 1/2 mGluR + ADHD • Objective: Identify optimal dose and confirm enhanced response in mGluR network mutation positive patients – Primary endpoints: ADHD RS, CGI - I – Powered to serve as pivotal trial – Top - line data anticip
Slide 23: ADHD Market Opportunity
ADHD Market Opportunity Overall US Market • 2015 Sales in excess of $10B* (> 60M total prescriptions**) • Approximately 6M pediatric patients • Stimulants dominate market with 90+% of total prescriptions NFC - 1 Opportunity • Genetic Biomarker identifies eligible patients (20 % of all ADHD) and resp
Slide 24: 22q11.2 Deletion Syndrome (DS) Overview
22q11.2 Deletion Syndrome (DS) Overview 24
Slide 25: Orphan Opportunity - 22q11.2 DS
Orphan Opportunity - 22q11.2 DS • 90% of 22q11.2DS patients have at least one mGluR network related deletion (RANBP1) 25 Micro deletion occurs in chromosome 22 Hypothesis: neuropsychiatric symptoms in 22q11.2DS patients are causally related to mGluR CNV/mutations and will respond to NFC - 1
Slide 26: Orphan Opportunity - 22q11.2 DS Symptoms
26 Orphan Opportunity - 22q11.2 DS Physical Symptoms • Heart defects • Cleft palate • Gastrointestinal problems • Poor wound healing • Skeletal abnormalities Surgical / medical therapies mortality <4% after CV surgery (excluding critically ill infants) No effective therapy Approx. 40% progress to sc
Slide 27: 22q11.2 Patient in GREAT Study
22q11.2 Patient in GREAT Study 27 T wo 22q11.2 p atients in the trial; one deletion and one duplication • Parents reported significant symptom improvement in both • M arked improvement in CGI - I and Vanderbilt • Both families elected to enroll in long - term safety trial to maintain access to NFC -
Slide 28: Orphan Pathway - 22q11.2 Deletion Syndrome
Orphan Pathway - 22q11.2 Deletion Syndrome • Phase 1/2 indication & dose finding study – File IND 4Q15 – Explore major neuropsychiatric disorders: ADHD, Anxiety, Mood – Initial data expected mid - 2016 – Transition to pivotal trial in one or more disorders – Rapid path to approval based on potential
Slide 29: Opportunity to work with the Leading 22q11.2 Center
Opportunity to work with the Leading 22q11.2 Center • “ 22q and You” Center at The Children’s Hospital of Philadelphia (CHOP) – World’s leading 22q11.2 Deletion Syndrome (DS) Center – Caring for > 1,300 children with a 22q11.2 deletion – Draws families from around the world – Staffed by geneticists,
Slide 30: Summary
Summary 30
Slide 31: Summary
NFC - 1 Summary • First program from the collaboration – Phase 2 ready program via neuroFix acquisition • P rogram in mGluR + ADHD is highly de - risked – Extensive safety database – Compelling Phase 1b efficacy signal in mGluR+ ADHD • Potential rapid path to approval in 22q11.2 DS – Potentially lar
Slide 32: Regulatory & IP Summary
Regulatory & IP Summary • Regulatory Exclusivity (approximately 7 years) – NFC - 1 has not been registered in the US – S hould receive New Chemical Entity status – 5 years Hatch - Waxman exclusivity – Additional 30 - month stay upon challenge – Potential for Orphan Indication in 22q11.2DS • IP Posit
Slide 33: Near-term Milestones
NFC - 1 Near - term Milestones 33 PROGRAM TIMING mGluR + ADHD GREAT Study Data presented at AACAP Oct 15 Request type “C” meeting with the FDA Q4 15 Initiate Phase 2/3 dose finding pivotal trial Q1 16 Initial data readout H2 16 22q11.2 Deletion Syndrome Submit IND for 22q11.2 DS Q4 15 Initiate explo
Slide 34: Appendix
Appendix 34
Slide 35: Glossary of Terms
Glossary of Terms 35 TERM DEFINITION CGI - S Clinical Global Impression – Severity. Clinician - rated assessment used to measure treatment effect. Used in all FDA regulated ADHD trials. CGI - I Clinical Global Impression – Improvement. Clinician - rated assessment used to measure treatment effect. U
Slide 36: mGluR: Important Components of Brain Signaling Network
mGluR : Important Components of Brain Signaling Network 36 • Widespread distribution and function makes mGluRs attractive drug targets for neuropsychiatric disease • K ey neuronal signaling functions regulated by mGluRs : • Cognition • Memory • Attention • Learning • Activity • Behavior • mGluR modu
Slide 37: GREAT Study Efficacy Measures and Results
NFC - 1 GREAT Study Efficacy Measures and Results Efficacy Measure Result Comments CGI - S Strong positive signal • Clinician was blinded to genetic tier CGI - I Strong positive signal • Clinician was blinded to genetic tier Vanderbilt (Parent) Strong positive signal • Only used the first 18 questio
Slide 38: GREAT Study Phase 1b Trial Design: Active Treatment Phase
NFC - 1 GREAT Study Phase 1b Trial Design: Active Treatment Phase 38 Part 2 5 - week Daily Dosing Weekly Dose - Escalation Notes: - S tudy was single blinded (to patient/family) - Animal tox initially limited the max exposure to 200 mg BID initially (per FDA) - 18/30 patients were titrated to the hi
Slide 39: 2015 TARGT EPO Milestones
2015 TARGT EPO Milestones 39 PROGRAM TIMING RENAL ANEMIA Complete enrollment in low dose MDGN - 201 cohort ✓ Initiate enrollment in mid dose MDGN - 201 cohort ✓ Initiate Phase 2 study in Peritoneal Dialysis (PD), including: ✓ - Renal Anemia Transplant patients - ESA Hypo - responsive patients Oral p
Slide 40: Medgenics Vision
Medgenics Vision 40 Driven by our commitment to patients we strive to create the premier rare and orphan disease company by : • Having unparalleled understanding of the underlying science of rare diseases from genotype to phenotype • Developing first - to - market or best - in - class therapies that